- Home
- GNTA vs SER Comparison
GNTA vs SER Comparison
Compare GNTA & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- SER
- Stock Information
- Founded
- GNTA 2014
- SER 2017
- Country
- GNTA Italy
- SER United States
- Employees
- GNTA N/A
- SER N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- SER Health Care
- Exchange
- GNTA Nasdaq
- SER Nasdaq
- Market Cap
- GNTA 59.7M
- SER 55.2M
- IPO Year
- GNTA 2021
- SER 2018
- Fundamental
- Price
- GNTA $3.18
- SER $4.81
- Analyst Decision
- GNTA
- SER Strong Buy
- Analyst Count
- GNTA 0
- SER 2
- Target Price
- GNTA N/A
- SER $13.00
- AVG Volume (30 Days)
- GNTA 8.2K
- SER 37.0K
- Earning Date
- GNTA 01-01-0001
- SER 11-11-2025
- Dividend Yield
- GNTA N/A
- SER N/A
- EPS Growth
- GNTA N/A
- SER N/A
- EPS
- GNTA N/A
- SER N/A
- Revenue
- GNTA N/A
- SER $130,000.00
- Revenue This Year
- GNTA N/A
- SER $134.46
- Revenue Next Year
- GNTA N/A
- SER N/A
- P/E Ratio
- GNTA N/A
- SER N/A
- Revenue Growth
- GNTA N/A
- SER N/A
- 52 Week Low
- GNTA $2.56
- SER $3.81
- 52 Week High
- GNTA $6.20
- SER $8.05
- Technical
- Relative Strength Index (RSI)
- GNTA 47.45
- SER 40.74
- Support Level
- GNTA $3.05
- SER $4.88
- Resistance Level
- GNTA $3.44
- SER $5.23
- Average True Range (ATR)
- GNTA 0.21
- SER 0.26
- MACD
- GNTA 0.03
- SER -0.04
- Stochastic Oscillator
- GNTA 52.04
- SER 3.73
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.